Table 1.
Baseline characteristics at enrollment in the open-label extension phase, after 24 months of treatment with etanercept (baseline CLIPPER2)
| eoJIA n = 55 |
ERA n = 31 |
PsA n = 23 |
Total n = 109 |
|
|---|---|---|---|---|
| % of CLIPPER | 92% (55/60) | 82% (31/38) | 79% (23/29) | 86% (109/127) |
| Age, yearsa | 10.6 (4.6) | 16.2 (1.6) | 15.8 (2.4) | 13.3 (4.5) |
| Femalea | 38 (69) | 5 (16) | 18 (78) | 61 (56) |
| JIA core set | ||||
| Physician Global Assessment of disease activity, 0–100 score |
1.0 (1.4) n = 49 |
0.7 (0.7) n = 30 |
0.8 (1.0) n = 19 |
0.8 (1.2) n = 98 |
| Number of active jointsa |
0.6 (1.0) n = 40 |
0.7 (1.2) n = 28 |
1.3 (4.6) n = 19 |
0.8 (2.3) n = 87 |
| Number of joints with LOMa |
0.8 (1.1) n = 40 |
1.4 (3.2) n = 28 |
1.7 (5.0) n = 19 |
1.2 (3.0) n = 87 |
|
C-reactive protein, mg/La (normal < 5 mg/L) |
3.9 (8.5) n = 47 |
2.7 (4.1) n = 27 |
1.1 (0.2) n = 18 |
3.0 (6.5) n = 92 |
| PtGA scorea | 1.4 (2.0) | 1.0 (1.3) | 1.3 (1.5) | 1.3 (1.7) |
| CHAQ scorea |
0.3 (0.6) n = 47 |
0.1 (0.2) n = 20 |
0.2 (0.3) n = 13 |
0.2 (0.5) n = 80 |
| JADAS 73 scorea |
3.5 (4.7) n = 37 |
2.3 (2.2) n = 25 |
3.3 (5.4) n = 18 |
3.1 (4.3) n = 80 |
| Additional measures | ||||
| Overall back pain VAS, mma |
– n = 0 |
2.3 (4.8) n = 26 |
– n = 0 |
2.3 (4.8) n = 26 |
| Nocturnal back pain VAS, mma |
– n = 0 |
2.1 (3.7) n = 26 |
– n = 0 |
2.1 (3.7) n = 26 |
| Psoriasis BSA, percentagea |
– n = 0 |
– n = 0 |
1.4 (2.4) n = 19 |
1.4 (2.4) n = 19 |
| PGA of psoriasisa |
– n = 0 |
– n = 0 |
0.6 (0.9) n = 19 |
0.6 (0.9) n = 19 |
| Baseline therapiesb | ||||
| Any DMARD | 50 (91) | 28 (90) | 19 (83) | 97 (89) |
| Methotrexate | 45 (82) | 17 (55) | 16 (70) | 78 (72) |
| Oral corticosteroid | 7 (13) | 7 (23) | 1 (4) | 15 (14) |
| Oral NSAID | 26 (47) | 19 (61) | 9 (39) | 54 (50) |
aMean (SD)
bNumber (percentage)
Abbreviations: BSA, body surface area; CHAQ, Childhood Health Assessment Questionnaire; DMARD, disease-modifying anti-rheumatic drug; eoJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related arthritis; JADAS, Juvenile Arthritis Disease Activity Score; JIA, juvenile idiopathic arthritis; LOM, limitation of motion; NSAID, non-steroid anti-inflammatory drug; PGA, Physician Global Assessment; PtGA, Patient/Parent Global Assessment; PsA, psoriatic arthritis; SD, standard deviation; VAS, visual assessment scale